Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May
Portfolio Pulse from Lisa Levin
U.S. stocks traded higher with the Nasdaq Composite gaining over 1%. The Core Personal Consumption Expenditure (PCE) price index rose 4.6% YoY in May 2023, slightly down from the expected 4.7%. Renalytix Plc, Baudax Bio, Inc., and Cyteir Therapeutics, Inc. saw their shares rise after various positive developments. Unicycive Therapeutics, Inc., Root, Inc., and Cineverse Corp. saw their shares drop due to various negative developments.
June 30, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baudax Bio shares rose 152% after the company agreed to acquire TeraImmune in a stock-for-stock transaction.
Acquisitions often lead to increased investor confidence and share price, especially if the acquired company has promising prospects.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Cyteir Therapeutics shares rose 37% after the company announced it is discontinuing all development of CYT-0851, dissolving the company and liquidating its assets.
While dissolution is usually a negative development, the liquidation of assets can lead to a temporary increase in share price due to potential payouts to shareholders.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Renalytix shares rose 33% after receiving FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
FDA approval for a product is a positive development, likely to boost investor confidence and share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Cineverse Corp. shares fell 17% after the company reported weak fourth-quarter sales.
Weak sales results can lead to a decrease in investor confidence and share price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
NEGATIVE IMPACT
Root, Inc. shares were down 16% after the company said it is not in receipt of any proposal that is either actionable or in the best interests of shareholders.
Lack of actionable proposals can indicate a lack of strategic direction or opportunities, leading to decreased investor confidence and share price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Unicycive Therapeutics shares dropped 24% after the company provided an update concerning its marketing application for lanthanum dioxycarbonate for hyperphosphatemia in chronic kidney disease patients on dialysis.
Negative updates on key products or applications can lead to a decrease in investor confidence and share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100